Plasma Concentrations of Clozapine and its Major Metabolites During Combined Treatment with Paroxetine or Sertraline

The effect of paroxetine or sertraline on steady-state plasma concentrations of clozapine and its major metabolites was studied in 17 patients with schizophrenia or schizoaffective disorder stabilized on clozapine therapy (200 - 400 mg/day). In order to treat negative symptomatology or concomitant depression, 9 patients received additional paroxetine (20 - 40 mg/day) and 8 patients sertraline (50 - 100 mg/day). After 3 weeks of paroxetine administration, mean plasma concentrations of clozapine and norclozapine increased significantly by 31 % (p < 0.01) and by 20 % (p < 0.05), respectively, while levels of clozapine N-oxide remained almost unchanged. The mean plasma norclozapine/clozapine and clozapine N-oxide/clozapine ratios were not modified during paroxetine treatment. No significant changes in plasma concentrations of clozapine and its major metabolites were observed after 3 weeks of combined therapy with sertraline. Clozapine coadministration with either paroxetine or sertraline was well tolerated. Our findings suggest that the metabolism of clozapine is not affected by sertraline treatment at typical therapeutic doses, while paroxetine, a potent inhibitor of CYP2D6, appears to inhibit the metabolism of clozapine, possibly by affecting pathways other than N-demethylation and N-oxidation. While sertraline may be added safely to patients on maintenance treatment with clozapine, careful clinical observation and monitoring of plasma clozapine levels may be useful whenever paroxetine is coadministered with clozapine.

References

• 1 Alderman J, Preskorn S H, Greenblatt D J, Harrison W, Penenberg D, Allison J, Chung M. Desipramine pharmacokinetics when coadministered with paroxetine or sertraline in extensive metabolizers.  J Clin Psychopharmacol. 1997;  17 284-291
• 2 Anghelescu I, Szegedi A, Schlegel S, Weigmann H, Hiemke C, Wetzel H. Combination treatment with clozapine and paroxetine in schizophrenia: safety and tolerability data from a prospective open clinical trial.  Eur Neuropsychopharmacol. 1998;  8 315-320
• 3 Avenoso A, Facciolá G A, Campo G M, Fazio A, Spina E. Determination of clozapine, N-desmethylclozapine, and clozapine N-oxide in human plasma by reverse phase high-performance liquid chromatography with ultraviolety detection.  J Chromatogr B Biomed Appl. 1998;  714 299-308
• 4 Avenoso A, Facciolá G, Scordo M G, Gitto C, Drago Ferrante G, Madia A G, Spina E. No effect of citalopram on plasma levels of clozapine, risperidone and their active metabolites in patients with chronic schizophrenia.  Clin Drug Invest. 1998;  16 393-398
• 5 Baumann P. Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors.  Clin Pharmacokinet. 1996;  31 444-469
• 6 Bertilsson L, Carrillo J A, Dahl M L, Llerena A, Alm C, Bondesson U. et al . Clozapine disposition covaries with the CYP1A2 activity determined by the caffeine test.  Br J Clin Pharmacol. 1994;  38 471-473
• 7 Brosen K, Hansen J G, Nielsen K K, Sindrup S H, Gram L F. Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine.  Eur J Clin Pharmacol. 1993a;  44 349-355
• 8 Brosen K, Skjelbo E, Rasmussen B B, Poulsen H E, Loft S. Fluvoxamine is a potent inhibitor of cytochrome P4501A2.  Biochem Pharmacol. 1993b;  45 1211-1214
• 9 Centorrino F, Baldessarini R J, Frankenburg F, Kando J, Volpicelli S A, Flood J G. Serum levels of clozapine and norclozapine in patients treated with selective serotonin reuptake inhibitors.  Am J Psychiatry. 1996;  153 820-822
• 10 Centorrino F, Baldessarini R J, Kando J, Frankenburg F R, Volpicelli S A, Puopolo P R, Flood J G. Serum concentrations of clozapine and its major metabolites: effects of cotreatment with fluoxetine or valproate.  Am J Psychiatry. 1994;  151 123-125
• 11 Crewe H K, Lennard M S, Tucker G T, Woods F R, Haddock R E. The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 activity in human liver.  Br J Clin Pharmacol. 1992;  34 262-265
• 12 Darchy A, Canceil O. Effet de la sertraline sur la clozapinémie.  Enchephale. 1998;  24 156-157
• 13 Edge S C, Markovitz J S, DeVane C L. Clozapine drug-drug interactions: a review of the literature.  Hum Psychopharmacol. 1997;  12 5-20
• 14 Eiermann B, Engel G, Johansson I, Zanger U M, Bertilsson L. The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapine.  Br J Clin Pharmacol. 1997;  44 439-446
• 15 Fischer V, Vogels B, Mauer R, Tynes R. The antipsychotic clozapine is metabolized by the polymorphic human microsomal and recombinant cytochrome P450 2D6.  J Pharmacol Exp Ther. 1992;  260 1355-1360
• 16 Freeman D J, Oyewumi L K. Will routine therapeutic drug monitoring have a place in clozapine therapy?.  Clin Pharmacokinet. 1997;  32 93-100
• 17 Gupta R N. Column liquid chromatographic determination of paroxetine in human serum using solid-phase extraction.  J Chromatogr B Biomed Appl. 1994;  661 362-365
• 18 Gupta R N, Dziurdzy S A. Therapeutic monitoring of sertraline.  Clin Chem. 1994;  40 498-499
• 19 Haring C, Fleishacker W W, Schett P, Humpel C, Barnas C. Influence of patient-related variables on clozapine plasma concentrations.  Am J Psychiatry. 1990;  147 1471-1475
• 20 Hiemke C, Weighmann H, Dahmen N, Wetzel H, Muller H. Elevated serum levels of clozapine after addition of fluvoxamine.  J Clin Psychopharmacol. 1994;  14 279-281
• 21 Jann M W, Grimsley S R, Gray E C, Chang W H. Pharmacokinetics and pharmacodynamics of clozapine.  Clin Pharmacokinet. 1993;  24 161-176
• 22 Jeppesen U, Gram L F, Vistisen K, Loft S, Poulsen K E, Brosen K. Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, floxetine, fluvoxamine and paroxetine.  Eur J Clin Pharmacol. 1993;  51 73-78
• 23 Jerling M, Lindstrom L, Bondesson U, Bertilsson L. Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: evidence from a therapeutic drug monitoring service.  Ther Drug Monit. 1994;  16 368-374
• 24 Joos A A B, Konig F, Frank U G, Kaschka W P, Morike K E, Ewald R. Dose-dependent pharmacokinetic interaction of clozapine and paroxetine in an extensive metabolizer.  Pharmacopsychiatry. 1997;  30 266-270
• 25 Kobayashi K, Yamamoto T, Chiba K, Tani M, Ishizaki T, Kuroiwa Y. The effects of serotonin reuptake inhibitors and their metabolites on S-mephenytoin 4-hydroxylase activity in human liver microsomes.  Br J Clin Pharmacol. 1995;  40 481-485
• 26 Kurz M, Hummer M, Kemmler G, Kurzthaler I, Saria A, Fleischhacker W W. Long-term pharmacokinetics of clozapine.  Br J Psychiatry. 1998;  173 341-344
• 27 Lane R M. Pharmacokinetic drug interaction potential of selective serotonin reuptake inhibitors.  Int Clin Psychopharmacol. 1996;  11 (suppl 5) 31-61
• 28 Linnet K, Oelsen O V. Metabolism of clozapine by cDNA-expressed human cytochrome P450 enzymes.  Drug Metab Dispos. 1997;  25 1379-1382
• 29 Ozdemir V, Naranjo C A, Herrmann N, Reed K, Sellers E M, Kalow W. Paroxetine potentiates CNS side effects of perphenazine: contribution of cytochrome P450 2D6 inhibition in vivo.  Clin Pharmacol Ther. 1997;  62 334-347
• 30 Pinninti N R, De Leon J. Interaction of sertraline with clozapine.  J Clin Psychopharmacol. 1997;  17 119-120
• 31 Plasky P. Antidepressant usage in schizophrenia.  Schizophr Bull. 1991;  17 649-657
• 32 Preskorn S H. Clinically relevant pharmacology of selective serotonin reuptake inhibitors: an overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism.  Clin Pharmacokinet. 1997;  32 (suppl 1) 1-21
• 33 Silver H, Nassar A. Fluvoxamine improves negative symptoms in treated chronic schizophrenia: an add-on double-blind, placebo controlled study.  Biol Psychiatry. 1992;  31 698-704
• 34 Sindrup S H, Brosen K, Gram L F. Pharmacokinetics of the selective serotonin reuptake inhibitor paroxetine: nonlinearity and relation to the sparteine oxidation polymorphism.  Clin Pharmacol Ther. 1992;  51 288-295
• 35 Spina E, Avenoso A, Facciolá G, Fabrazzo M, Monteleone P, Maj M, Perucca E, Caputi A P. Effect of fluoxetine on plasma concentrations of clozapine and its major metabolites in patients with schizophrenia.  Int Clin Psychopharmacol. 1998;  13 141-145
• 36 Spina E, Avenoso A, Facciolà G, Scordo M G, Ancione M, Madia A G, Ventimiglia A, Perucca E, Caputi A P. Relationship between plasma concentrations of clozapine and norclozapine and therapeutic response in patients with schizophrenia resistant to conventional neuroleptics.  Psychopharmacology. 2000;  148 83-89
• 37 Spina E, De Domenico P, Ruello C, Longobardo N, Gitto C, Ancione M, Di Rosa A E, Caputi A P. Adjunctive fluoxetine in the treatment of negative symptoms in chronic schizophrenic patients.  Int Clin Psychopharmacol. 1994;  9 281-285
• 38 Sproule B A, Naranjo C A, Bremner K E, Hassan P C. Selective serotonin reuptake inhibitors and CNS drug interactions. A critical review of the evidence.  Clin Pharmacokinet. 1997;  33 454-471
• 39 Taylor D, Ellison Z, Ementon Shaw L, Wickham H, Murray R. Coadministration of citalopram and clozapine: effect on plasma clozapine levels.  Int Clin Psychopharmacol. 1998;  13 19-21
• 40 Von Moltke L, Greenblatt D J, Cotreau-Bibbo M, Harmatz J S, Shader R I. Inhibition of alprazolam metabolism in vitro: effects of the serotonin reuptake inhibitor antidepressants, ketoconazole and quinidine.  Br J Clin Pharmacol. 1994;  38 23-31